The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia
Authors:
- Mitchell J. BartlettMBMitchell J. Bartlett
- Omar S. MabroukOMOmar S. Mabrouk
- Lajos SzabòLSLajos Szabò
- Andrew J. FloresAFAndrew J. Flores
- Kate L. ParentKPKate L. Parent
- Jean M. BidlackJBJean M. Bidlack
- Michael L. HeienMHMichael L. Heien
- Robert T. KennedyRKRobert T. Kennedy
- Robin PoltRPRobin Polt
- Scott J. ShermanSSScott J. Sherman
- Torsten FalkTFTorsten Falk
Open Access
- 22 December 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (1) , 20
Abstract
In previous work we evaluated an opioid glycopeptide with mixed μ/δ-opioid receptor agonism that was a congener of leu-enkephalin, MMP-2200. The glycopeptide analogue showed penetration of the blood–brain barrier (BBB) after systemic administration to rats, as well as profound central effects in models of Parkinson’s disease (PD) and levodopa (L-DOPA)-induced dyskinesia (LID). In the present study, we tested the glycopeptide BBI-11008 with selective δ-opioid receptor agonism, an analogue of deltorphin, a peptide secreted from the skin of frogs (genus Phyllomedusa). We tested BBI-11008 for BBB-penetration after intraperitoneal (i.p.) injection and evaluated effects in LID rats. BBI-11008 (10 mg/kg) demonstrated good CNS-penetrance as shown by microdialysis and mass spectrometric analysis, with peak concentration levels of 150 pM in the striatum. While BBI-11008 at both 10 and 20 mg/kg produced no effect on levodopa-induced limb, axial and oral (LAO) abnormal involuntary movements (AIMs), it reduced the levodopa-induced locomotor AIMs by 50% after systemic injection. The N-methyl-D-aspartate receptor antagonist MK-801 reduced levodopa-induced LAO AIMs, but worsened PD symptoms in this model. Co-administration of MMP-2200 had been shown prior to block the MK-801-induced pro-Parkinsonian activity. Interestingly, BBI-11008 was not able to block the pro-Parkinsonian effect of MK-801 in the LID model, further indicating that a balance of mu- and delta-opioid agonism is required for this modulation. In summary, this study illustrates another example of meaningful BBB-penetration of a glycopeptide analogue of a peptide to achieve a central behavioral effect, providing additional evidence for the glycosylation technique as a method to harness therapeutic potential of peptides.Keywords
Funding Information
- Michael J. Fox Foundation for Parkinson's Research (No number)
- National Institute on Drug Abuse (R43DA026653 and R44 DA026653)
This publication has 55 references indexed in Scilit:
- CNS penetration of the opioid glycopeptide MMP-2200: A microdialysis studyNeuroscience Letters, 2012
- Effects of the novel glycopeptide opioid agonist MMP-2200 in preclinical models of Parkinson's diseaseBrain Research, 2011
- In Vivo Characterization of MMP-2200, a Mixed δ/μ Opioid Agonist, in MiceThe Journal of Pharmacology and Experimental Therapeutics, 2011
- MK-801 inhibits l-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonismNeuropharmacology, 2010
- Alterations in opioid receptor binding in Parkinson's disease patients with levodopa‐induced dyskinesiasAnnals of Neurology, 1997
- Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's diseaseMovement Disorders, 1994
- Identification and characterization of two dermorphins from skin extracts of the Amazonian frog Phyllomedusa bicolorFEBS Letters, 1992
- D 1 and D 2 Dopamine Receptor-regulated Gene Expression of Striatonigral and Striatopallidal NeuronsScience, 1990
- Binaltorphimine and nor-binaltorphimine, potent and selective k-opioid receptor antagonistsLife Sciences, 1987
- Evidence for a Selective Processing of Proenkephalin B into Different Opioid Peptide Forms in Particular Regions of Rat Brain and PituitaryJournal of Neurochemistry, 1984